黄素对口腔疾病的治疗作用:一个系统性审查
Novi Indriyani1, Nanan Nur'aeny2
1Oral Medicine Residency, Faculty of Dentistry, Universitas Padjadjaran, Bandung, Indonesia.
Clinical pharmacology : advances and applications
|March 4, 2025
概括
黄素是一种草本提取物,有效地减少了口腔疾病的严重程度,疼痛和病变大小. 它具有抗炎,抗氧化和伤口愈合的特性,对各种口腔疾病有益.
科学领域:
- 药理学 药理学是指药理学的学科.
- 口腔医学是指口腔医学.
- 自然产品 自然产品
背景情况:
- 黄素来自草本植物,在治疗包括口腔疾病在内的各种疾病方面表现有前途.
- 存在多种黄素配方,为口腔疾病管理提供治疗选择.
研究的目的:
- 审查黄素在减少口腔疾病严重程度,疼痛评分和病变大小方面的治疗效果.
- 阐明黄素在口腔条件下发挥治疗作用的机制.
主要方法:
- 系统审查遵循系统审查和元分析 (PRISMA) 准则的首选报告项目.
- 在PubMed,Science Direct和Scopus搜索了2014年至2024年间发表的随机对照试验 (RCT).
- 包括21个RCT,涉及1244名参与者,重点是全文英语文章.
主要成果:
- 黄素最常被研究的是口腔下纤维化 (OSMF),显示出抗炎和原酶抑制作用.
- 研究证实了黄素在治疗各种口腔疾病方面的显著疗效.
- 确定的其他特性包括抗氧化剂,抗真菌和治疗口腔白血病,复发性口腔口腔炎 (RAS),口腔平坦 (OLP) 和假牙口腔炎等疾病的伤口愈合能力.
结论:
- 黄素表现出抗炎,抗氧化,原酶抑制,抗真菌和伤口愈合的特性.
- 这些特性有助于减少患有口腔疾病的患者的病变严重程度,疼痛评分和大小.
- 黄素是治疗OSMF,粘膜炎,白血病,RAS,OLP和假牙牙炎的有前途的治疗剂.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
130
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
130
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
362
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
362
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:29Drugs for Treatment of Ulcerative Colitis in IBD
116
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
116
01:26Peptic Ulcer Disease IV: Management
58
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
58
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
326
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
326